Related Experiment Video
Updated: Apr 6, 2026
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Genetics and Biology of Pancreatic Ductal Adenocarcinoma
Richard F Dunne1, Aram F Hezel1
1Division of Hematology/Oncology, Wilmot Cancer Institute, University of Rochester Medical Center, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA.
Abstract:
Pancreatic ductal adenocarcinoma remains a clinical challenge. Thus far, enlightenment on the downstream activities of Kras, the tumor's unique metabolic needs, and how the stroma and immune system affect it have remained untranslated to the clinical practice. Given the numbers of diverse therapies in development and a growing knowledge about how to evaluate these systems preclinically and clinically, this is expected to change significantly and for the better over the next 5 years.
Insights
Pancreatic ductal adenocarcinoma (PDAC) presents significant clinical challenges. Advances in understanding Kras, tumor metabolism, stroma, and immune interactions are expected to improve patient outcomes within five years.
Area of Science:
- Oncology
- Cancer Biology
- Immunology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) remains a difficult-to-treat malignancy.
- Key aspects like Kras signaling, metabolic vulnerabilities, and the tumor microenvironment (stroma and immune cells) are critical but poorly understood in clinical practice.
Purpose of the Study:
- To highlight the current challenges in translating preclinical and clinical knowledge of PDAC into effective patient therapies.
- To emphasize the potential for significant clinical improvements in PDAC treatment over the next five years.
Main Methods:
- This study is a review and perspective piece, synthesizing current knowledge.
- It discusses the evaluation of PDAC systems through preclinical and clinical studies.
Main Results:
- Despite extensive research, the clinical application of findings regarding Kras, tumor metabolism, stroma, and immune interactions in PDAC is limited.
- Numerous therapies are under development, with improved preclinical and clinical evaluation methods.
Conclusions:
- The integration of knowledge on Kras, tumor metabolism, stroma, and immune dynamics is crucial for advancing PDAC treatment.
- Significant clinical progress in managing PDAC is anticipated in the near future due to ongoing research and therapeutic development.
